tradingkey.logo

Lifecore Biomedical Inc

LFCR
查看詳細走勢圖
7.570USD
+0.010+0.13%
收盤 02/06, 16:00美東報價延遲15分鐘
283.62M總市值
虧損本益比TTM

Lifecore Biomedical Inc

7.570
+0.010+0.13%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.13%

5天

-12.89%

1月

-4.30%

6月

-2.07%

今年開始到現在

-7.46%

1年

+23.49%

查看詳細走勢圖

TradingKey Lifecore Biomedical Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Lifecore Biomedical Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名72/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為8.75。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Lifecore Biomedical Inc評分

相關信息

行業排名
72 / 159
全市場排名
190 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看跌

Lifecore Biomedical Inc亮點

亮點風險
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
業績高增長
公司營業收入穩步增長,連續3年增長24.79%
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-7.28,處於3年歷史低位
機構減倉
最新機構持股28.16M股,環比減少6.07%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉2.60K股

分析師目標

基於 5 分析師
買入
評級
8.750
目標均價
+15.74%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Lifecore Biomedical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Lifecore Biomedical Inc簡介

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
公司代碼LFCR
公司Lifecore Biomedical Inc
CEOJosephs (Paul)
網址https://www.lifecore.com/
KeyAI